Liquid Biopsy in Solid Malignancy

Matthew Scarlotta, Cem Simsek, Amy Kim

Research output: Contribution to journalArticlepeer-review


The clinical utility of tissue biopsies in cancer management will continue to expand, especially with the evolving role of targeted therapies. "Liquid biopsy" refers to testing a patient's biofluid samples such as blood or urine to detect tumor-derived molecules and cells that can be used diagnostically and prognostically in the assessment of cancer. Many proof-of-concept and pilot studies have shown the clinical potential of liquid biopsies as diagnostic and prognostic markers which would provide a surrogate for the conventional "solid biopsy". In this review, we focus on three methods of liquid biopsy-circulating tumor cells, extracellular vesicles, and circulating tumor DNA-to provide a landscape view of their clinical applicability in cancer management and research.

Original languageEnglish (US)
Pages (from-to)284-296
Number of pages13
JournalGenetic Testing and Molecular Biomarkers
Issue number4
StatePublished - Apr 1 2019


  • cancer
  • circulating DNA
  • circulating tumor cells
  • extracellular vesicles
  • liquid biopsy

ASJC Scopus subject areas

  • Genetics(clinical)

Fingerprint Dive into the research topics of 'Liquid Biopsy in Solid Malignancy'. Together they form a unique fingerprint.

Cite this